Added to YB: 2025-10-28
Pitch date: 2025-10-24
GSK [neutral]
GSK plc
+12.82%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 72.9B
Pitch Price
GBP 16.17
Price Target
N/A
Dividend
3.36%
EV/EBITDA
8.93
P/E
13.65
EV/Sales
2.70
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 24/10/2025 - GSK – Pipeline progress
GSK (update): Shingrix gets EU approval for convenient prefilled format (1.7m annual EU shingles cases); tebipenem Phase III met primary endpoint for cUTIs (2.9m US cases/yr); Ventolin low-carbon inhaler launches 2026; Blenrep approved by FDA for multiple myeloma (180k global cases/yr). 66 pipeline assets, 9.2x 2026 P/E, 4.3% yield.
Read full article (2 min)